Company news

Immuron Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immuron North American Q1 Sales Up 111% YoY

October 13, 2019

US Defense funds AU$5.5M for Immuron New Gastro Weapon

October 1, 2019

US Defense Reports Immuron Travelan Targets Cholera

September 3, 2019

Appendix 4E & Annual Report to shareholders

August 30, 2019

Immuron Reports Results in SAH Clinical Trial

August 7, 2019

Underwritten Public Offer

July 17, 2019

Immuron Prices Underwritten Public Offering of ADSs

July 17, 2019

Proposed Public Offer of IMRN ADSs

July 16, 2019

Immuron North American revenue surges by 52% in FY19

July 16, 2019

US DoD Reports Results from Travelan Shigellosis Study

June 12, 2019

Preliminary Prospectus Supplement filed with SEC

May 24, 2019

Trading halt

May 23, 2019

Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors

April 16, 2019

Immuron sales surge by 66% in the Third Quarter of FY19

April 14, 2019

Immuron Aims to Secure FDA Approval for IMM-124E

April 10, 2019

Company Update on CDI Clinical Trial and New Strategic Focus

March 18, 2019

Travelan FY19 Update and Expansion into North America

January 28, 2019

Form F-3

January 14, 2019

Immuron Receives $1.19M R&D Tax Concession Refund

January 2, 2019

IMC Appoints Experienced US Based Biotech Executive as CEO

November 18, 2018

NASH clinical trial presentation & continued revenue growth

November 9, 2018

US DoD Report Travelan Protects Against Shigella in Primates

September 4, 2018

Immuron Reports Record Revenue

July 25, 2018

US Department of Defense Research Collaboration Moves Ahead

July 15, 2018

European Patent Gramted for Nash Treatment

July 11, 2018

Immuron Announces Board Appointment

June 26, 2018

IMC Preclinical Study Reports Reduction in Colitis Symptoms

May 8, 2018

Travelan Sales Continue to Soar in Third Quarter of FY2018

April 23, 2018

Immuron Announces A$5.1M Private Placement to U.S. Fund

March 13, 2018

Immuron Reports Positive Results in NASH Clinical Trial

March 7, 2018

Correction to False and Misleading News Release

March 6, 2018

Appendix 4D - Half Year Financial Report - 31 Dec 2017

February 27, 2018

Travelan Revenue Grows Significantly in US and Australia

February 16, 2018

US Defence Depart Report-Travelan Targets Priority Pathogens

January 29, 2018

Immuron to Receive $2.16M R&D Tax Concession Cash Refund

January 22, 2018

Immuron Granted US Patent for NASH Treatment

November 13, 2017

Immuron Successfully Completes NASH Phase II Clinical Study

November 8, 2017

Travelan Experiences Strong Q1 FY2018 Sales Growth

November 7, 2017

Appendix 4E Preliminary Final Report (30 June 2017)

August 31, 2017

Immuron Opens Clinical Site to Commence C.Diff CDI Study

August 28, 2017

Immuron Approved to Commence Clinical Study in C.Difficile

August 9, 2017

Immuron to Present C.difficile Data at ClostPath 2017 Confer

August 8, 2017

Immuron Announces Management Changes

August 3, 2017

Success of NASH Phase II Interim Analysis Explained Further

July 13, 2017

NASH PhaseII Interim Analysis Reveals Improved Liver Enzymes

July 10, 2017

Pre-Clinical C. difficile Infection Results Paper Published

July 3, 2017

IMC Prices US IPO and NASDAQ Listing Raising USD$6.1M

June 9, 2017

Travelan Increases Industry Presence - Conf & Sales Update

June 2, 2017

Immuron Secures $1.5M R&D Cash Advance Loan Funding

June 1, 2017

NASDAQ Listing on Hold Pending NASH Interim Analysis Results

May 31, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 105 decks. Every deck is listed under its year.